Bioxcel Therapeutics, Inc. · NASDAQ:BTAI
Bioxcel Therapeutics — Technical Presentation (February 2023)
5 slides from Bioxcel Therapeutics's technical presentation, Feb 21, 2023
Slide 1: BXCL701 Key Opinion Leader Day
BioXcel Therapeutics | 555 Long Wharf Drive, 12th Floor | New Haven, CT 06511 | www.bioxceltherapeutics.com ® BXCL701 Key Opinion Leader Day February 21, 2023 NASDAQ: BTAI
Slide 2: Forward-looking statements
This presentation includes "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1
Slide 3: BXCL701: Pipeline Within a Product Plan and Next-Generation Candidate
BXCL701: Pipeline Within a Product Plan and Next-Generation Candidate 73 *Investigator Sponsored Trial Compound Proposed Indication Preclinical Phase 1 Phase 2 Expected Upcoming Milestone Collaborator BXCL701 Small Cell Neuroendocrine Prostate Cancer (SCNC) Initiate Phase 2b Small Cell Lung Cancer (
Slide 4: SCNC Clinical Development Timeline
2023 2024 2025 1H 2H 1H 2H 1H 2H SCNC Clinical Development Timeline* 76 SCNC Phase 2b pivotal study NDA Submission Under AA Program *Initial discussions with the FDA regarding the development pathway and registrational strategy for BCXL701 in SCNC expected in mid-2023. | AA = Accelerated Approval
Slide 5: SCLC Clinical Development Timeline
SCLC Clinical Development Timeline 2023 2024 2025 1H 2H 1H 2H 1H 2H Phase 1b SCLC PoC End of Phase 2 meeting
BioXcel Therapeutics — Technical Presentation (February 2023) on 6ix